Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ionis Pharmaceuticals, Inc. (IONS : NSDQ)
 
 • Company Description   
Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

Number of Employees: 1,402

 
 • Price / Volume Information   
Yesterday's Closing Price: $75.56 Daily Weekly Monthly
20 Day Moving Average: 1,929,289 shares
Shares Outstanding: 165.26 (millions)
Market Capitalization: $12,487.27 (millions)
Beta: 0.38
52 Week High: $86.74
52 Week Low: $32.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.98% -3.00%
12 Week -6.25% -13.34%
Year To Date -4.49% -11.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2855 GAZELLE COURT
-
CARLSBAD,CA 92010
USA		 ph: 760-931-9200
fax: 760-603-2700		 ir@ionis.com https://ionis.com
 
 • General Corporate Information   
Officers
Brett P. Monia - Chief Executive Officer
Joseph Loscalzo - Chairman of the Board
Elizabeth L. Hougen - Executive Vice President; Finance and Chief Financ
Allene M. Diaz - Director
Joan E. Herman - Director

Peer Information
Ionis Pharmaceuticals, Inc. (GSAC)
Ionis Pharmaceuticals, Inc. (CASIF)
Ionis Pharmaceuticals, Inc. (ALCD.)
Ionis Pharmaceuticals, Inc. (OMNN)
Ionis Pharmaceuticals, Inc. (CGPI.)
Ionis Pharmaceuticals, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 462222100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 07/29/26
Share - Related Items
Shares Outstanding: 165.26
Most Recent Split Date: (:1)
Beta: 0.38
Market Capitalization: $12,487.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/29/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 25.41
Price/Cash Flow: -
Price / Sales: 11.80
EPS Growth
vs. Year Ago Period: 39.78%
vs. Previous Quarter: 60.28%
Sales Growth
vs. Year Ago Period: 86.36%
vs. Previous Quarter: 21.18%
ROE
03/31/26 - -58.65
12/31/25 - -68.82
09/30/25 - -44.26
ROA
03/31/26 - -10.07
12/31/25 - -12.34
09/30/25 - -8.65
Current Ratio
03/31/26 - 4.10
12/31/25 - 3.83
09/30/25 - 2.79
Quick Ratio
03/31/26 - 4.09
12/31/25 - 3.81
09/30/25 - 2.78
Operating Margin
03/31/26 - -30.91
12/31/25 - -40.36
09/30/25 - -26.45
Net Margin
03/31/26 - -30.91
12/31/25 - -40.36
09/30/25 - -26.45
Pre-Tax Margin
03/31/26 - -30.73
12/31/25 - -40.22
09/30/25 - -26.73
Book Value
03/31/26 - 2.97
12/31/25 - 3.02
09/30/25 - 3.82
Inventory Turnover
03/31/26 - 2.02
12/31/25 - 1.57
09/30/25 - 1.10
Debt-to-Equity
03/31/26 - 2.75
12/31/25 - 2.76
09/30/25 - 0.96
Debt-to-Capital
03/31/26 - 73.30
12/31/25 - 73.37
09/30/25 - 49.09
 

Powered by Zacks Investment Research ©